Strong evidence. Real impact.
Decades of research and real-world data support better breast cancer treatment decisions and outcomes.
View All Studies- 180+
Publications & abstracts
- 23,000+
Patients enrolled in FLEX study
- 45+
Countries using Agendia tests
- 7
Guidelines recognized
FOR PROVEN RESULTS
Trusted by leading physicians and institutions around the world
NEWS
Press Releases
Ready to take the next step?
Order MammaPrint® + BluePrint® genomic tests to assess recurrence risk and tumor biology and help guide early-stage breast cancer treatment decisions.